Sanjivani Paranteral Ltd.
BSE: SANJIVIN · Pharmaceuticals · sector
₹148.70BSE close 2026-10-26
Key numbers
Market cap₹183 cr
Price₹148.70
52w high / low₹244 / ₹126
P/E17.5xSector median 27.9x
P/B3.8xSector median 2.9x
Book value₹39.3
Dividend yield0.34%Sector median 0.48%
ROE24.1%Sector median 11.7%
ROCE22.9%Sector median 12.3%
OPM19.1%Sector median 14.0%
Debt / equity0.30xSector median 0.16x
EV/EBITDA13.2xSector median 18.6x
Interest cover15.6x
Current ratio1.38x
Sales growth 3y+24.6%Sector median +9.6%
Profit growth 3y+14.1%Sector median +13.3%
PEG2.58x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1 cr vs borrowings ₹14 cr (FY26): borrowings are higher by ₹13 cr.
- Operating profit covered interest 15.6x in the last 12 months.
- Other income was 12% of net profit in the last 12 months.
- Dividend paid in 1 of the last 5 financial years.
- Price ₹148.70 on 2026-10-26: -39.1% from the 52-week high, +18.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹375.50 · low ₹133.75
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 18 | 18 | 18 | 22 | 13 | 24 |
| EBITDA | 3 | 3 | 5 | 4 | 2 | 4 |
| OPM % | 14.4% | 14.8% | 28.4% | 17.4% | 12.0% | 17.5% |
| Other income | 0 | 0 | 0 | 0 | 1 | 0 |
| Net profit | 2 | 2 | 5 | 3 | 1 | 2 |
| EPS (₹) | 1.84 | 1.46 | 3.78 | 2.21 | 0.49 | 2.03 |
| Revenue YoY | -27.3% | +33.3% | ||||
| Profit YoY | -74.9% | +39.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 31 | 35 | 54 | 70 | 69 | 78 |
| EBITDA | 6 | 6 | 8 | 10 | 10 | 15 |
| Net profit | 5 | 5 | 6 | 8 | 7 | 10 |
| EPS (₹) | 4.85 | 4.51 | 5.28 | 6.89 | 5.49 | 8.51 |
| Revenue growth | +15.9% | +53.3% | +28.8% | -2.0% | – | |
| Profit growth | -7.0% | +36.8% | +31.1% | -17.3% | – | |
| Dividend / share (₹) | – | – | – | – | 0.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +24.6% | – | – |
| Net profit | +14.1% | – | – |
| EPS | +6.8% | – | – |
| Share price | – | -22.9% (2y) | -22.9% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 38 | 48 |
| Borrowings | 8 | 14 |
| Cash & equivalents | 2 | 1 |
| Total assets | 78 | 88 |
| Fixed assets | 21 | 47 |
| Capital work in progress | 19 | 0 |
| Investments | 0 | 1 |
| Receivables | 17 | 15 |
| Inventory | 11 | 11 |
| Payables | 15 | 4 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 12 | 0 |
| Cash from investing | -20 | -10 |
| Cash from financing | 9 | 10 |
| Capex | 30 | 10 |
| Free cash flow | -18 | -10 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 21.3% | 13.9% |
| ROCE % | 23.7% | 16.3% |
| Debtor days | 87 | 82 |
| Inventory days | 95 | 92 |
| Payable days | 138 | 31 |
| Cash conversion cycle (days) | 44 | 143 |
| Working capital days | 12 | 53 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SANJIVIN | ₹183 cr | 17.5x | 3.8x | 24.1% | 22.9% | 19.1% | +24.6% | 0.34% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2025-09-19 | Dividend | Dividend Rs 0.5 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SANJIVIN |
| BSE code | 531569 |
| ISIN | INE860D01013 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.